Disruptive, next-generation healthcare strategies, including the ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG), are scuffling this year, but those struggles belie opportunity — something the healthcare sector is ripe with.

The broader healthcare sector is delivering solid performances this year, but innovative exchange traded funds, such as ARKG, are being left behind as the growth spots of healthcare, including biotechnology equities, are being left behind.

The good news for investors considering ARKG is that the healthcare sector still offers a lot to like and could be a source of credible long-term upside.

“The sector has many favorable long-term attributes, such as new cost-saving and care-improving advances in medical technologies, an aging global population, and a growing middle class in emerging-market economies—all of whom will demand more extensive drug treatments and medical care over time,” says David Kastner of Charles Schwab.

The actively managed ARKG focuses on companies engaged in agricultural biology, bioinfomatics, CRISPR, molecular diagnostics, and targeted therapeutics, among other innovative corners of the healthcare sector. Due to the fact that many of the concepts represented in ARKG are new by the standards of the healthcare space, healthcare disruptors rarely trade at discounted multiples, but there’s some evidence that some ARKG member firms may be discounted relative to their histories of lofty valuations.

“Valuations are relatively attractive, and balance sheets in the sector are generally in good shape, increasing the possibility of higher dividend payments, share-enhancing stock buybacks, and mergers-and-acquisition (M&A) activity,” adds Schwab’s Kastner.

Broadly speaking, shareholder rewards don’t apply to ARKG components. In this case, that’s alright because investors should prioritize genomics companies that are investing in research and development, not those saddled by dividend obligations.

However, some of ARKG’s 53 components are attractively valued, while others are credible takeover targets. The latter point is one to watch in 2022 because large-cap pharmaceuticals companies are flush with cash and need to bolster product pipelines and fight off patent cliffs. With prices depressed on some ARKG components, it’s possible that the ETF’s roster could be fertile ground for mergers and acquisitions activity in 2022.

Over 63% of ARKG’s components, as of the end of the third quarter, are mid- and small-cap stocks, underscoring the point that the fund could be an epicenter of takeover activity and speculation next year.

For more news, information, and strategy, visit the Disruptive Technology Channel.

The opinions and forecasts expressed herein are solely those of Tom Lydon, and may not actually come to pass. Information on this site should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any product.